Home » Stocks » CMPI

Checkmate Pharmaceuticals, Inc. (CMPI)

Stock Price: $6.17 USD 0.10 (1.65%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $6.05 -0.12 (-1.95%) May 13, 5:39 PM
Market Cap 131.27M
Revenue (ttm) n/a
Net Income (ttm) -42.91M
Shares Out 21.63M
EPS (ttm) -4.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $6.17
Previous Close $6.07
Change ($) 0.10
Change (%) 1.65%
Day's Open 6.10
Day's Range 5.85 - 6.27
Day's Volume 32,801
52-Week Range 5.84 - 23.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolo...

3 days ago - GlobeNewsWire

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technolo...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technol...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technol...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

1 month ago - GlobeNewsWire

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

Other stocks mentioned: AGRX, CYTH, GORO, RYTM, WINT, WMPN
1 month ago - InvestorPlace

CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary techno...

2 months ago - GlobeNewsWire

Robert F. Dolski appointed as Chief Financial Officer

4 months ago - GlobeNewsWire

About CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorp... [Read more...]

Industry
Biotechnology
IPO Date
Aug 7, 2020
Stock Exchange
NASDAQ
Ticker Symbol
CMPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CMPI stock is "Buy." The 12-month stock price forecast is 24.75, which is an increase of 301.13% from the latest price.

Price Target
$24.75
(301.13% upside)
Analyst Consensus: Buy